Abstract
Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Current Pharmaceutical Biotechnology
Title: Fibrinolytic Factors in Liver Fibrosis
Volume: 12 Issue: 9
Author(s): Liang-I Kang and Wendy M. Mars
Affiliation:
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Abstract: Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Export Options
About this article
Cite this article as:
Kang Liang-I and M. Mars Wendy, Fibrinolytic Factors in Liver Fibrosis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281036
DOI https://dx.doi.org/10.2174/138920111798281036 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism Leptin as Clinical Target
Recent Patents on Inflammation & Allergy Drug Discovery Wireless Sensor Networks:The Biggest Cross-Community Design Exercise To-Date
Recent Patents on Computer Science Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview
Current Medicinal Chemistry Impact of Nutrition Transition and Resulting Morbidities on Economic and Human Development
Current Diabetes Reviews From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Pleiotropic Beneficial Effects of Epigallocatechin Gallate, Quercetin and Delphinidin on Cardiovascular Diseases Associated with Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Twin-to-Twin Transfusion Syndrome: From Placental Anastomoses to Long-Term Neurodevelopmental Outcome
Current Pediatric Reviews Translational Insight Into Polycystic Ovary Syndrome (PCOS) From Female Monkeys with PCOS-like Traits
Current Pharmaceutical Design Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
Current Topics in Medicinal Chemistry Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Neuroimaging of the Vulnerable Plaque
Current Vascular Pharmacology Hemodynamic Regulation of Metallopeptidases within the Vasculature
Protein & Peptide Letters Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology